Aptevo Therapeutics
APVO
2 hedge funds and large institutions have $1.13M invested in Aptevo Therapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
17% less capital invested
Capital invested by funds: $1.36M → $1.13M (-$234K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$822K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$822K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$18.7K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$17.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $2 | – | – | – |
|
|
27
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$17.8K | – | – |
|
|
28
Citadel Advisors
Miami,
Florida
| – | -$18.7K | – | – |
|
APVO Hedge Fund Activity: Q3 2023 in Review
2 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q3 2023, worth a combined $1.13M — down 17% from $1.36M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new APVO positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $822K. The largest seller was Citadel Advisors, cutting an estimated $18.7K.
- 2 institutional investors held Aptevo Therapeutics (APVO) as of Q3 2023, up from 0 in Q2 2023.
- Funds reported $1.13M of Aptevo Therapeutics stock for Q3 2023, down 17% quarter-over-quarter.
- 2 funds opened new Aptevo Therapeutics positions in Q3 2023 and 0 closed out, a net change of +2 holders.
- The largest Aptevo Therapeutics buyer in Q3 2023 was Armistice Capital, an estimated $822K added.
- The largest Aptevo Therapeutics seller in Q3 2023 was Citadel Advisors, an estimated $18.7K sold.
Based on aggregated 13F filings for Q3 2023.